Indeed, we found that the IL-17 GES also correlates with the presence of other oncogenic mutations in MAPK genes including NRAS, KRAS and NF1. However, we still found several tumor samples with high IL-17 GES, in which we could not detect common MAPK driver mutations by expanded targeted next-generation sequencing genotyping. The gene discussed is KRAS; the disease is neoplasm.